Predictive Oncology (POAI) Announces Positive Results from Recent Study Utilizing AI To Predict Cancer Patient Outcomes, Up ~40%.
    Predictive Oncology (POAI) Announces Positive Results from Recent Study Utilizing AI To Predict Cancer Patient Outcomes, Up ~40%.
    PRISM View

    May 28, 2024 - by Ashlee Vogenthaler

    Predictive Oncology (POAI) Announces Positive Results from Recent Study Utilizing AI To Predict Cancer Patient Outcomes, Up ~40%.

    28 May 2024

    New York, May 28, 2024 - PRISM MarketView - The AI driven drug discovery company, Predictive Oncology, Inc. (POAI) announced positive results from a recent study whose purpose was to determine if POAI could utilize its AI capabilities and machine learning (ML) models to more accurately predict short- and long-term survival outcomes amongst ovarian cancer patients.

    Predictive Oncology Inc. - Prism MarketView

    The leading edge of a new frontier in drug discovery As a science-driven company on the leading edge of oncology drug discovery, Predictive Oncology

    Read More

    Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

    Study successfully demonstrated Predictive’s ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alonePITTSBURGH, May 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from a retrospective study that the company recently completed in collaboration with UPMC Magee-Womens Hospital will be presented at t

    Read More

    This study was completed in collaboration with UPMC Magee-Women’s Hospital and will e presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 – June 4th in Chicago, IL.
    “…The ability to employ ML to better predict patient prognoses may help with clinical management and monitoring and could serve as a decision support tool to better tailor treatment plans to individual patients. The results of this important study strongly support continued development of such ML models and subsequent incorporation into daily clinical practice,” stated, Robert Edwards, MD, Professor and Chair, Department of Obstetrics, Gynecology & Reproductive Sciences, Co-Director, Gynecologic Oncology Research, Magee-Womens Hospital of UPMC.
    Upon the announcement, shares of Predictive have traded up over 40% and currently leads the PRISM NextGen Tech and AI Index.
    About PRISM MarketView
    Established in 2020, PRISM MarketView is dedicated to monitoring and analyzing small-cap stocks in emerging sectors. We offer up-to-the-minute financial news, provide comprehensive investment tools, and foster a dynamic community of investors. Central to our offerings are proprietary indices that track emerging sectors, including biotechnology, clean energy, next-generation technology, medical devices, and more. Visit us at prismmarketview.com and follow us on Twitter.
    To see this content properly accept cookies.
    Disclaimer:
    PRISM MarketView is not a registered or authorized broker-dealer or investment advisor and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
    Contact:
    PRISM MarketView
    info@prismmarketview.com
    646-863-6341
    Prism MarketView | Stock Market News and Investment Opportunities
    To see this content properly accept cookies.
    PRISM MarketView - Social Media (X)
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.